Patient characteristics according to the line of immunotherapy, MSI, and PD-L1 CPS

Line of immunotherapyMedian number of cyclesPatients with MSI-H, n (22.3%)Patients with MSS and PD-L1 CPS ≥ 1, n (51.2%)All patients, n (100%)
120526
212172458
3652540
430511
53056
62011

MSI-H: high microsatellite instability; MSS: microsatellite stable; PD-L1: programmed death-ligand 1; CPS: combined positive score